secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001493152-23-019393
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech enters research agreement with Japan's NIID to study Ampligen's effect on viral shedding
--------------------------------------------------------------------------------

- Agreement with Japanese National Institute of Infectious Disease to evaluate Ampligen's capacity to prevent viral shedding in respiratory virus infections.
- AIM supplies Ampligen free of charge; NIID conducts research; quarterly oral updates and final written report within 60 days.
- Intellectual property ownership follows US inventorship law; no automatic license granted to NIID.
- Agreement terminates upon completion, written agreement, or one year from effective date (May 8, 2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315223019393/0001493152-23-019393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315223019393/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-019393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer